Jane Elizabeth-Brown Reusch, M. D




Скачать 166.21 Kb.
НазваниеJane Elizabeth-Brown Reusch, M. D
страница1/3
Дата конвертации28.02.2013
Размер166.21 Kb.
ТипДокументы
  1   2   3

CURRICULUM VITAE

Jane Elizabeth-Brown Reusch, M.D.


PERSONAL INFORMATION

Professional address and phone: Denver VA Medical Center (111H), Rm 9c120b

1055 Clermont Street

Denver, CO 80220

(303) 399-8020 x 3137

FAX: 393-5271

PRESENT POSITION

Professor, Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, and Biochemistry, University of Colorado Denver-HSC, Staff Physician, Denver VAMC, and Director, Diabetes Team, and Microscopy Core Denver VAMC, Denver, CO; CCTSI VA Liaison


EDUCATION

College:

University of Notre Dame 1977-1981

Bachelor of Science Cum Laude

Medical School:

Northwestern University 1982-1984

Chicago, IL

University of Minnesota 1984-1986

Minneapolis, MN

Doctor of Medicine

Medical Internship and Residency:

University of Colorado Affiliated Hospitals 1986-1989

Denver, CO

Fellowship in Endocrinology & Metabolism:

University of Colorado Health Sciences Center 1989-1992

Denver, CO

Instructor of Medicine:

University of Colorado Health Sciences Center 1992-1994

Director, UCHSC Diabetes Clinical Practice 1992-1997

Assistant Professor of Medicine:

University of Colorado Health Sciences Center 1994-2000

Associate Professor of Medicine

University of Colorado Health Sciences Center 2000- 2006

Professor of Medicine

University of Colorado Health Sciences Center 2006-Present

BOARD CERTIFICATION

Internal Medicine 1989

Endocrinology & Metabolism 1991, 2002


MEDICAL LICENSURE

Colorado

HONORS/AWARDS

Bachelor of Science cum laude

Associate Investigator Award, Veterans Administration (1992-1995)

NRSA (1992-1995) declined

WAFCR/WSCI Young Investigator Award (February 1993)

WAFCR Young Faculty Research Award (1994)

Research Associate Award, Veterans Administration (1995-1998)

NIH Clinical Investigator Award (1995-2000)

VA Merit Review Award (1995-2009)

ADA Research Award (1998-2001)

Elected, Western Society for Clinical Investigation (1999)

Merck Young Investigator Award in Atherosclerosis (1999)

American Heart Association- Writing Group on Diabetic Vascular Disease (2000)

American Diabetes Association-First Annual Colorado Woman of Valor Award (2001)

President American Federation of Medical Research (2002-2003)

Elected, American Society for Clinical Investigation (2002)

Juvenile Diabetes Research Foundation International Research Award (2002-2005)

UCHSC Student Teaching Award (2001-2002)

Elected, Western Association of Physicians (2004)

NIH RO1 (2004-2009)

Elected, Association of American Physicians (2005)

President, WSCI (2008)

VA Clinical Merit Review Award (2007-2011)

MEDICAL SOCIETIES


American College of Physicians

American Diabetes Association

American Federation for Medical Research

The Endocrine Society

American Heart Association

Juvenile Diabetes Research Foundation

American Society for Clinical Investigation and Western Society for Clinical Investigation

American Association of Physicians and Western Association of Physicians


GRANT SUPPORT (ACTIVE )

VA Clinical Merit Award (Reusch) (10/01/2007-09/30/2011)

Role: PI

Title: Impact of lipid infusion on Functional Exercise Capacity

Objective: To reconstitute the defect in exercise capacity observed in diabetes by inducing a dysmetabolic state


HL56481 (Stenmark) (Program Project) PPG Adaptations to Hypoxia (4/1/98-3/31/14)


POI HL-14985-29 (Klemm, Reusch)

Role: Co-investigator Direct Costs: $207,000 (PO1)

“Adaptations to Hypoxia”

Major Goals: Our section of the Program Project will investigate the molecular mechanisms by which PPARg agonists prevent the loss of CREB in pulmonary artery smooth muscle cells. Our section will also evaluate the ability of CREB to control macrophage recruitment to the arterial wall in pulmonary hypertension.


DK57516 (Eisenbarth) Bridge Funding

Diabetes Education and Research Center

Role: Executive Committee Member


ADA Clinic Research Grant (Regensteiner) (1/2008-12/2010)

Role: Co-investigator

Title: Influence of endothelial dysfunction on central vs peripheral causes of exercise impairment in Type 2 Diabetes

Objective: To define to contribution of diabetes related endothelial dysfunction to impaired exercise capacity in diabetes


UL1 RR025780 (Sokol) NIH/NCRR Colorado CTSI

Associate co-director for education and career development

VA CCTSI Liaison

Goal: To create a local infrastructure to foster successful recruitment and retention of translational scientists


Amylin/Lilly Investigator Initiated clinical trial (10/2010 – 9/2012)

Role Co-PI (Reusch /Regensteiner)

Title: Effect of GLP-1 on Exercise Capacity

Objective: Pilot study to examine the impact of a GLP-1 analog on exercise function


GSK Investigator Initiated Grants Program 4/1/04-3/31/10 (3% no salary)

Role: Co-Principal Investigator (Reusch, Regensteiner, Durbin)

GCRC Protocol #:  1380

Title: Rosiglitazone Therapy In The Prevention of Coronary Artery Disease In Patients With Impaired Glucose Tolerance (enrollment complete in follow-up phase)

Objective: To examine the impact of PPAR gamma ligands on exercise function and coronary calcium score in persons with IGT.

Support: $398,000 direct and $496,000 total (based on pt enrollment)


Mentorship Grants:

Kristen Nadeau MD: NIH K23 “Examination of Fuel Partitioning and Exercise Capacity in Children”; CNRU, PGCTRC, CTSI, CWHR local seed grants; JDRF innovation; NIH TODAY(local PI)

JDRF Mentored Career Development Award in Clinical Research;

Cecelia Wang MD: VA CDA1/2: “Insulin Resistance and Diabetic Vascular disease”


Rebecca Ohm: Endocrine Society Summer Internship: “Role of CREB in Diabetic Neuropathy”

Yolanda Bogaert MD PhD: VA CDA2 “Role of Matrix Proteins in Diabetic Vascular Disease”

Irene Schauer MD PhD Lilly Endocrine Society Scholar award: GCRC P&F, CNRU P&F; DOM small grant, BIRWCH K12 (1/2008-12/2010); CCTSI pilot

NIH K23 (Score 16-funding decision in 2011)

Timothy Bauer PhD NRSA “O2 Delivery and utilization in T2DM” (6/2007-12/2008)

Kerrie Moreau PhD CTSI mentor based grant

Christina Garlington GEMS Award (NIH and the Endocrine Society)


Recently completed funding:

NIH RO1 DK064741-01 (4/01/04-3/31/09) No cost extension

Support: Direct: 196,101 (4/4/04-3/31/05) (4/15/04-2/28/2009): Direct 1,081,460 Total 1,566.663

Role: PI

Title Transcriptional Regulation of PDGF Receptor Alpha

Objective: To determine the impact of loss of vascular CREB function vascular gene regulation and atherosclerosis


Juvenile Diabetes Research Foundation (Reusch)

Downregulation of CREB in Neurons by Diabetes Induced Oxidative Stress

Role: PI

Support: Direct 4/1/02-3/30/03 163,000 Total 540,000 (4/01/02-3/31/05)

Major goal is to evaluate oxidative stress mediated neuronal injury and gene regulation


VA REAP Neurodegeneration (Tyler.) (10/1/98-3/31/2005)

Role: Co-investigator

Support: Direct $200,000/yr Total $ 1,050,000

“Role of Apoptosis in Neurodegenerative Diseases”


GSK Grants Program (Reusch/Regensteiner) (10/1/01-9/1/03)

Investigator Initiated Research Proposal GlaxoSmithKline

Role: Co PI

Support: Direct $135,000 Total $170,000

Project: Effects of Rosiglitazone on Maximal Oxygen Consumption in Persons with Type 2 Diabetes Mellitus



VA Merit Award (Reusch) (10/01/1995-09/30/2008)

Role: PI

“Role of CREB in Diabetic Vascular Disease”

Goal: To define the impact of diabetes on vascular function and gene regulation


Merck Med School Grant (Reusch, O’Brien)

CREB Downregulation by Hypercholesterolemia

Role: PI

Support: Direct $73,000 Total: 85,000

Goal: To determine the impact of HMG CoA Reductase Inhibitors on SMC CREB downregulation in LDLR-/- mice.


Takeda Investigator Initiated Grants Program 11/01/03-10/31/09 (3% no salary)

Role: Principal Investigator

Title: PPAR gamma Regulation of Beta Cell Survival
Protocol No.:   028-03R

Support: 184,000 direct and 224,000 total

Objective: To define the mechanism of beta cell protection by PPAR gamma.


Industry initiated clinical trials: (full list per request)


COMMITTEES

Denver VAMC: 1) Nutrition Committee - Chairman 1992-2000

2) Research & Development Committee 6/93-6/2001

3) Biosafety/Biohazard Committee - Chairman 1996-2003

4) Diabetes Center Committee - Director 95-Present

5) Biannual Patient Forum on Diabetes Self Management: Chairman (2000-2004)

6) Chairman, Committee for Ongoing Research Productivity at DVAMC/Fitzsimons UCHSC

7) Microscopy core director 2005-present

8) CCTSI- VA Liaison 2008-2013

UCHSC: 1) Director, UCHSC-BDC Diabetes Center Initiative 1994

2) Director, UCHSC Diabetes Clinical Practice 1994-1998

3) Intern selection Committee 1999-Present

4) Cardiology Division Head Search committee

5) DOM research day committee 2006

6) DOM small grants review committee 2004-2006

7) Renal Division Head search committee

8) RAC 2006-2009 (chair 2007-2008)

9) Vascular Biology Center Initiative –Director

10) Center for Women’s Health Research-Senior Advisor

CTSA: 1) Co-director Education section 2008-2013

2) VA Liaison to the CCTSI and executive committee member

3) K club and K Nuts and Bolts director

4) Steering committee of the TL1 and KL2 (mentoring committee)

ADA: 1) Annual Clinical Diabetes Meeting - Co-Chairman 94, 96, 97

2) Annual Diabetes Institute Meeting - Planning Committee 93-Present

3) Member, Colorado Community Board 98-Present

4) National Grant Review – Study Section Ad hoc-1996, 1997: Member 1999- 2001; ad hoc 2002, 2006, 2007, 2008, 2009

5) Abstract Review for national meeting 2007-2010

AFMR: 1) WAFCR Abstract Review & Session Chairman 93-97

2) University of Colorado AFCR Representative/National Council 96-99

3) National Co-Chair for Public Policy 98-2003

4) Grant Review 1997-2004

5) Chair, WAFMR 200-2001, Sec-Treas WAFMR, 1997-1999

6) President National AFMR, 2002-2003; Foundation President AFMR, 2003-2004

7) Member Clinical Research Roundtable Advisory Group on Associations

8) Western Society for Clinical Investigation (Council 2003-2006)

9) Program Founder and Director: Fellow and Junior Faculty Scholars Award Program (2002-2010)

Colorado Department of Public Health:

1) Member, Diabetes Advisory Council 95-97

2) Chairman, State Diabetes Advisory Council 1998-2002

3) Advisor, First Peer Review Panel of Colorado

4) State of Colorado Diabetes Initiative Steering Committee Co-chairman, 2000-2002

VA National: Endocrinology Study Section 2001-2004, VA CDA study section 2006

FASEB: National Meeting Planning Committee (2002-2004)

Endocrine Society Rep to FASEB Science Policy Board (Research Affairs-Clinical Research chair- 2005-2008)

Endocrine Society: Research Affairs Committee (Clinical Research Subcommittee) (2003-2008)

AHA Women’s Leadership Council ATVB (2005-2008)

Abstract review annual meeting (2007-2009)

NIH 2007- Ad Hoc Reviewer (R 21 RFA for DM Biomarkers (3/07); Ad Hoc Molecular mechanisms of Atherosclerosis (8/07): CSR open house workshop: Integrated Biology (9/07): Ad hoc R21RFA- Clinical innovation in DM (3/09; 7/09; 11/09; 4/10; 7/10)

EFF Grant review (2004-2010)


EDITORIAL BOARD: Endocrinology, 1997-2001, Journal of Investigative Medicine 2000-2004; J Biological Chemistry 2007-2012

Ad Hoc Reviewer: AJCN, Endocrinology, Diabetes Care, Journal of Clinical Investigation, Neuroscience, Western Journal of Medicine, Endocrine Journal, Journal of Neuroimmunology, Diabetes, Archives Internal Medicine, Journal of Biological Chemistry, Diabetologia, Annals of Internal Medicine, Circulation, Molecular Pharmacology, Circulation Research, Metabolism, J Immunology, BBA, ATVB, Circulation, Endocrine Reviews, Science


TEACHING:

Endocrine Pathophysiology 1991-present (MSII)

Diabetes I and II 1993-1996 (Physical Therapy Students)

Management of Diabetes in Primary Care 1994-2008 (Residents and Faculty)

Diabetic Emergencies 1994-2001, 2005, 2008 (Residents)

Diabetic Complications 1996-2001 (Residents)

Ward Attending 1996-2010

Endocrine Ward Attending 1995-2010

Director of Nurse Practitioners Diabetes Center Team 1996-Present

Diabetes Management 1994-2001, 2004, 2005, 2007, 2008, 2009 (VA clinic Residency group)

Pharmacological Approach to Diabetes 1996-2010 (MSIV, VA Pharmacists, VA CBOC)

Carbohydrate metabolism 1998-1999; (physiology graduate students)

Pathogenesis in Practice (MS IV) 2002

Biochemistry Clinical Correlate in Carbohydrate Metabolism (1996, 2004, 2005) (MS1)

Carbohydrate metabolism (fellow basic science lecture series) 2000-2010

Academic Career Development (DOM, DOP, MS I and ER) 2004-2009

Integrative Physiology journal review series 2005-2010 (MSTP) Course director Angie Ribera

Carbohydrate and Lipid metabolism section director and lecturer (Graduate School 2006, 2009-2010) Course director Joan Hooper

Career Trajectories – Integrated Clinicians course (MSIV) 2008-2010 Lisa Schilling course director

Clinical Pharmacology (MS IV) (1998-2011)


CONSULTANT/ADVISORY PANELS:

SmithKline Beecham – IMPACT Group; Diabetes and Atherosclerosis working group

Merck – Diabetes and Cardiovascular Advisory Panel; Diabetes Process of Care Advisory Panel

Colorado Diabetes Initiative SUMMIT Meeting: Co-chair of initiative and State Steering committee- Diabetes Grassroots Initiative for Colorado

American Heart Association: Diabetic Vascular Disease Panel

IOM and Clinical Research Roundtable (Advisory Panel: Challenges Facing the Clinical Research Enterprise: The Response of Medical Specialty and Clinical Research Societies, September 2003)

GSK DPP IV Clinical Advisory Board, 2004

GSK Diabetes Drug Development Advisory Panel 2005-presernt

Takeda Diabetes Drug Development Advisory Panel 2005, 2008

GSK International Incretin Advisory Panel 2006, 2009-2012

Amylin Cardiovascular Disease Advisory Panel 2006


INVENTIONS:

Published Patent Application: US 2004/0097454 A1

May 20, 2004

“Method of Modulation of Cell Phenotype”

Jane EB Reusch and Dwight Klemm

PUBLICATIONS (Peer Reviewed)

1. Roemeling RV, Olshefski R, Langevin T, Berestka J, Reusch JJ, Reusch JE, Lakatua D, Wick MR, Hrushesky WJ. Cisplatin chromotherapy and disulfiram rescue reduce toxicity without interfering in anti cancer activity: animal findings and preliminary clinical experiences. Chronobiology International. 1986;3(1):55-64.

2. Reusch J, Begum N, Sussman KE, Draznin B. Regulation of GLUT-4 phosphorylation by intracellular calcium in adipocytes. Endocrinology. 1991;129:3269-3273.

3. Reusch JE-B, Kleinschmidt-DeMasters BK, Lillehei KO, Rappe D, Gutierrez-Hartmann A. Preoperative diagnosis of lymphocytic hypophysitis (Adenohypophysitis) unresponsive to short course dexamethasone: case report. Neurosurgery. 1992;30:268-72.

4. Reusch JE-B, Sussman KE, Draznin B. Inverse relationship between GLUT-4 phosphorylation and its intrinsic activity. Journal of Biological Chemistry. 1993;268:3348-51.

5. Begum N, Leitner W, Reusch JE-B, Sussman KE, Draznin B. GLUT-4 phosphorylation and its intrinsic activity: Mechanism of Ca2+-induced inhibition of insulin-stimulated glucose transport. Journal of Biological Chemistry. 1993;268:3352-6.

6. Reusch JE-B, Hsieh P, Klemm D, Hoeffler J, Draznin B. Insulin inhibits dephosphorylation of adenosine 3’, 5’ monophosphate response element-binding protein/activating transcription factor-1: Effect on nuclear phosphoserine phosphatase-2a. Endocrinology. 1994;135:2418-22.

7. Reusch JE-B, Bhuripanyo P, Carel K, Leitner JW, Hsieh P, DePaolo D, Draznin B. Differential requirement for p21Ras activation in the metabolic signaling by insulin. Journal of Biological Chemistry. 1995;270:2036-40.

8. Reusch JE-B, Hsieh P, Bhuripanyo P, Carel K, Leitner JW, Olefsky JM, Draznin B. Insulin inhibits nuclear phosphatase activity: Requirement for the C-terminal domain of the insulin receptor. Endocrinology. 1995;136:2464-9.

9. DePaolo D, Reusch JE-B, Carel K, Bhuripanyo P, Leitner JW, Draznin B. Functional interactions of phosphatidylinositol 3-kinase with GTPase-activating protein in 3T3-L1 adipocytes. Molecular & Cellular Biology. 1996;16:1450-7.

10. Carel K, DePaolo D, Reusch JE-B, Leitner JW, Draznin B. Reduced phosphorylation of mitogen-activated protein kinase in response to insulin in cells with truncated C terminal domain of insulin receptor. Endocrinology. 1996;137:2362-6.

11. Klemm DJ, Roesler WJ, Boras T, Colton LA, Felder K, Reusch JE-B. Insulin stimulates cAMP-response element binding protein activity in HepG2 and 3T3-L1 cell lines. Journal of Biological Chemistry. 1998;273:917-23.

12. Reusch JE-B. Focus on insulin resistance in NIDDM: Therapeutic implications. Diabetes Educator. 1998 Mar;24:188-93.

13. Pugazhenthi S, Boras T, O’Connor D, Meintzer MK, Heidenreich KA, Reusch JE-B. IGF-I signaling to CREB in neuronal tissue involves redundant signaling pathways. Journal of Biological Chemistry. 1999;274:2829-37.

14. Regensteiner JG, Bauer TA, Reusch JE-B, Brandenburg SL, Sippel JT, Vogelsong AM, Smith

S, Wolfel EE, Eckel RH, Hiatt WR. Abnormal oxygen uptake kinetic responses in Type 2

diabetes mellitus: Evidence for an early defect. Journal of Appl Physiol. 1998 Jul 1;85(1):310-7

15. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: Design and Methods for a Clinical Trial in the Prevention of Type 2 Diabetes Mellitus Diabetes Care-22. 1999;623-34.

16. Reusch JEB and Klemm DJ. Nutrition and Fat Cell Differentiation. (editorial) Endocrinology. 1999;140, 2935-7.

17. Brandenburg SL, Reusch JE-B, Bauer TA, Jeffers BW, Hiatt WR, Regensteiner JG. Effects of Exercise Training on Oxygen Uptake Kinetic Responses in Women with Type 2 Diabetes. Diabetes Care 22. 1999;1640-6.

18. Pugazhenthi S, Miller E, Sable C, Young P, Heidenreich KA, Boxer LM, Reusch JEB. Insulin-like Growth Factor 1 Induces bcl-2 promoter through the Transcription Factor cAMP response element binding protein. Journal of Biological Chemistry. 1999;274:27529-35.

19. Reusch JEB, Colton L, Klemm DJ. CREB is Necessary and Sufficient for Adipocyte Differentiation. Mol Cell Biol. 2000 Feb;20(3):1008-20.

20. Subbiah Pugazhenthi, Albina Nesterova, Carol Sable*, Kim A Heidenreich, Linda M Boxer, Lynn E Heasley, Jane E-B Reusch. Akt/Protein Kinase B mediated cell survival involves transcriptional upregulation of bcl-2. Journal of Biological Chemistry. 2000;275:10,761-6.

21. Brandenberg SL, Reusch JEB, Felder KK, Nelson-Wong E, Lindenfeld J, Manco-Johnson M, Regensteiner JG. Impaired Fibrinolysis in premenopausal women and Age-matched Men with Type 2 diabetes mellitus. J Investig Med. 2002 Mar;50(2):110-5.

22. Klemm DJ, Leitner W, Nesterova A, Reusch JE, Goalstone ML, Draznin B. Insulin –induced Adipocyte Differentiation: Activation of CREB rescues adipogenesis from the arrest caused by inhibition of prenylation. Journal of Biological Chemistry. 2001;276(30):28430-5.

23. Dwight J. Klemm, Peter A. Watson, Maria G. Frid, Edward C. Dempsey, Jerome Schaack2, Lillester A. Colton, Albina Nesterova2, Kurt R. Stenmark, Jane E.-B. Reusch. CREB Content is a Molecular Determinant of Smooth Muscle Cell Proliferation and Migration. Journal of Biological Chemistry. 2001;276: 46,142-50.

24. Watson, P.A., Nesterova, A. Burant C.., Klemm, D.J., and Reusch, J. E-B. Diabetes-Related Changes in CREB Content Enhance Smooth Muscle Cell Proliferation and Migration. Journal of Biological Chemistry. 2001;276:46,132-41.

25. Reusch J E, Klemm DJ. Inhibition of cAMP-response element-binding protein activity decreases B/Akt expression in 3T3-L1 adipocytes and induces apoptosis. Journal of Biological Chemistry. 2002 Jan 11;277(2):1426-32.

26. Watson PA, Vinson C, Nesterova A and Reusch JEB. Content and activity of cAMP response element-binding protein regulate platelet-derived growth factor receptor-alpha content in vascular smooth muscles. Endocrinology. 2002 Aug;143(8):2922-9.

27. Pugazhenthi S, Nesterova A, Purevsuren J, Auderserirk G, Kern M, Cabell L, Eves E, Rosner MR, Boxer LM, Reusch JEB. Oxidative Stress Mediated Downregulation of CREB in Hippocampal Neurons J Neurochem. 2003 Mar;84(5):982-96.

28. Jambal P, Masterson S, Nesterova A, Bouchard R, Bergman B, Hutton JC, Boxer LM, Reusch JEB and Pugazhenthi S. Cytokine-mediated Down-regulation of The Transcription Factor cAMP-response element-binding protein in Pancreatic beta-cells. J Biol Chem. 2003 Jun 20;278(25):23055-65.

29. Haskins K, Bradley B, Powers K, Fadok V, Flores S, Ling T, Pugazhenthi S, Reusch JEB, Kench J. Oxidative Stress in Type 1 Diabetes. Ann N Y Acad Sci. 2003 Nov;1005:43-54.

  1. Vaishnav D, Jambal P, Reusch JEB, Pugazhenthi S. SP600125, an inhibitor of c-jun N-terminal kinase, activates CREB by a p38 MAPK-mediated pathway. Biochem Biophys Res Commun. 2003 Aug 8;307(4):855-60.

  2. Reusch JEB and Klemm DJ Focused Perspective. CREB in the vessel wall: Good or Bad? Circulation. 2003;103:1164-6.

  3. Reusch JEB. Diabetes, microvascular complications, and cardiovascular complications: What is it about glucose? Commentary, J Clin Invest. 2003 Oct;112(7):986-8.

33. Regensteiner JG, , Popylisen s, Bauer T, Lindenfeld J, Gill R, Smith S, Oliver-Pickett CK, Reusch JEB, Weil J. Oral L-arginine and Vitamins E and C improve endothelial function in women with type 2 diabetes. Vascular Medicine. 2003;8(3):169-75.

  1. Haskins K, Kench J, Powers K, Bradley B, Pugazhenthi S, Reusch JEB, McDuffie M. Role for oxidative stress in Regeneration of Islet Beta Cells? J Investigative Medicine. 2004 Jan;52(1):45-9.

  2. McCall DT, Barton P, Hamman RF, Reusch JE and Sauaia A. Are Low-Income Elderly Patients at Risk for Poor diabetes Care? Diabetes Care. 2004 May;27(5):1060-5.

  3. Watt WC, Sakano H, Lee ZY, Reusch JE, Trinh K, Storm DR. Odorant Stimulation Enhances Survival of Olfacotory Neurons via MAPK and CREB Neuron. 2004 March 25;41(6):955-67. PMID: 15046727

  4. Arany,I, Megyesi JK, Reusch JEB, and Safirstein RL. CREB mediates ERK-induced survival of mouse renal tubular cells after oxidant stress. Kidney Int. 2005 Oct;68(4):1573-82 PMID: 16164634

  5. Richard M. Bergenstal, MD 1Soma S. Nag, PhD 2Jane E.B Reusch, MD 3Shiva G. Sajjan, PhD 2Charles M. Alexander, MD 2. Macrovascular Risk Factors and Treatment Strategies In the Diabetes Process of Care Study Endocrine Practice. 2005 May-Jun;11:172-9. PMID: 16239203

  6. Regensteiner Judith, Bauer Tim and Reusch Jane EB. Improved Exercise Capacity with An Insulin Sensitizer in Type 2 Diabetes. Diabetes Care. 2005 Dec; 28(12):2877-83. PMID: 16306548

  7. Nadeau KJ, Ehlers LB, Aguirre LE, Moore RL, Jew KN, Ortmeyer HK, Hansen BC, Reusch JE, Draznin B. Exercise training and calorie restriction increase SREBP-1 expression and intramuscular triglyceride in skeletal muscle. Am J Physiol Endocrinol Metab. 2006 Jul; 291(1):E90-8. PMID: 16449296

  8. Garat CV, Fankell D, Erickson PF, Reusch JEB, Bauer N, McMurtry I, Klemm DJ. Platelet-Derived Growth Factor BB Induces Nuclear Export and Proteasomal Degradation of CREB via Phosphatidylinositol 3-Kinase/Akt Signaling in Pulmonary Artery Smooth Muscle Cells. Mol Cell Biol. 2006 Jul;26(13):4934-48. PMID: 16782881

  9. Singh U, Devaraj S, Dasu MR, Ciobanu D, Reusch JEB and Jialal I. C-Reactive Protein Decreases Interleukin-10 Secretion in Activated Human Monocyte-Derived Macrophages via Inhibition of Cyclic AMP Production. Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2469-75. PMID: 16917108

  10. Crossno J, Garat C, Reusch J, Morris K, Dempsey E, McMurtry I, Stenmark K, Klemm D Rosiglitazone Attenuates Hypoxia-Induced Pulmonary Arterial Remodeling. Am J Physiol Lung Cell Mol Physiol. 2007 Apr;292(4):L885-97. PMID: 17189321

  11. Watson PA, Reusch JEB, McCune SA, Leinwand LA, Luckey SW, Konhilas JP, Brown DA, Chicco AJ, Sparagna GC, Long CS, Moore RL. Restoration of CREB Function is Linked to Completion and Stabilization of Adaptive Cardiac Hypertrophy in Response to Exercise. Am J Physiol Heart Circ Physiol. 2007 Jul; 293(1):H246-59. PMID: 17337597

  12. Sarkar SA, Gunter J, Bouchard R, Reusch JE, Wiseman A, Gill RG, Hutton JC, Pugazhenthi S. Dominant negative mutant forms of the cAMP response element binding protein induce apoptosis and decrease the anti-apoptotic action of growth factors in human islets.” Diabetologia. 2007 Aug; 50(8):1649-59. PMID: 17593347

  13. Bauer TA, Reusch JE, Levi M, Regensteiner JG “Skeletal Muscle Deoxygenation After the Onset of Moderate Exercise Suggests Slowed Microvascular Blood Flow Kinetics in Type 2 Diabetes.” Diabetes Care. 2007 Nov;30(11):2880-5. PMID: 17675540

  14. Nadeau KJ, Ehlers LB, Aguirre LE, Reusch JE, Draznin B. “Discordance between intramuscular triglyceride and insulin sensitivity in skeletal muscle of Zucker diabetic rats after treatment with fenofibrate and rosiglitazone.” Diabetes Obes Metab. 2007 Sep;9(5):714-23. PMID: 17697064

  15. Regensteiner JG, Groves B, Reusch JEB, Bauer TA, Quaife R, Miller t, Smith S, Wolfel EE Evidence of Cardiac Dysfunction during Exercise in Women with Uncomplicated Type 2 Diabetes Medicine, Science, Sport and Exercise 2009 May;41(5):977-84 PMID: 19346991

  16. Nadeau, KJ, Zeitler PS, Bauer, TA, Brown MS, Dorosz JL, Draznin, B, * Reusch JEB, * Regensteiner JG Insulin resistance in adolescents with Type 2 diabetes is associated with impaired exercise capacity. Oct;94(10):3687-95. Epub 2009 Jul 7.PMID: 19584191

  17. Nadeau, KJ, Zeitler PS, Bauer, TA, Brown MS, Dorosz JL, Draznin, B, * Regensteiner JG, * Reusch JEB Insulin resistance in patients with type 1 diabetes: Implications for cardiovascular exercise function J Clin Endocrinol Metab. 2009 Nov 13. [Epub ahead of print]PMID: 19915016

  18. Schauer IA, Reusch JEB “Acute activation of CREB by FFA in vascular smooth muscle cells is independent of ROS” Metabolism. 2009 Mar;58(3):319-27 PMID: 19217446

  19. Irene E. Schauer, Leslie A. Knaub, Peter A. Watson, Catherine Gliwa, Katherine E. Lewis, Alan Chait, Dwight J. Klemm, Jody M. Gunter, Ron Bouchard, Thomas O. McDonald, Kevin D. O’Brien, Jane E.B. Reusch CREB Downregulation in vascular disease: a common response to cardiovascular risk (ATVB- 2010 in press) PMID: 20150559

  20. Venkatachalam K, Venkatesan B, Valente AJ, Melby PC, Nandish S, Reusch JE, Clark RA, Chandrasekar B. “Wisp1, a pro-mitogenic, pro-survival factor, mediates TNF-alpha stimulated cardiac fibroblast proliferation, but inhibits TNF- alpha -induced cardiomyocyte death.” J Biol Chem. 2009 May 22;284(21):14414-27 PMID: 19339243

  21. Rosenstock, Julio; Reusch, Jane; Bush, Mark; Yang, Fred The Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A Randomized Controlled Trial Exploring Weekly, Biweekly, and Monthly Dosing Diabetes Care 2009 Oct;32(10):1880-6PMID: 19592625

  22. Huebschmann AG, Reis EN, Emsermann C, Dickinson LM, Reusch JE, Bauer TA, Regensteiner JG Women with type 2 diabetes perceive harder effort during exercise than nondiabetic women Appl Physiol Nutr Metab. 2009 Oct;34(5):851-7 PMID: 19935846

  23. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study Curr Med Res Opin. 2009 Oct;25(10):2361-71.PMID: 19650752

  24. Garat, C.V., J.T. Crossno, Jr., T.M. Sullivan, J.E.B. Reusch and D.J. Klemm. 2010. Thiazolidinediones Prevent PDGF-BB-Induced CREB Depletion in Pulmonary Artery Smooth Muscle Cells by Preventing Upregulation of Casein Kinase 2’ Catalytic Subunit. J Cardiovasc Pharmacol. 2010 May;55(5):469-80. PMID 20147842



BOOK

Regensteiner JG, Stewart K, Reusch JEB, Veves A “Diabetes and Exercise”, Humana Press. 2009.


REVIEWS AND CHAPTERS


1. Draznin B, Reusch J, Begum N, Sussman K, Byyny R, Ohara T: Calcium, insulin action, and insulin resistance. Excerpta Medica, International Congress Series, Elsevier Publishers 980:225-245, 1991.

2. Reusch JE-B, Begum N, Draznin B: Cytosolic calcium as an intracellular mediator of insulin resistance. IN: The Hypertensive Diabetic in Focus; Parving HH (ed); Bayer AG, Leverkusen, Germany (publisher), 1993.

3. Reusch JE-B: Glut-4 phosphorylation: Effects of phosphorylation on glucose transport and intrinsic activity. IN: Molecular Biology of Diabetes, Part II; Draznin B, LeRoith D (eds); The Humana Press, Totowa, NJ, 24:497-510, 1994.

4. Reusch JE-B, Begum N, Draznin B: Cytosolic calcium as an intracellular mediator of insulin resistance. Cardiovascular Risk Factors 4:3-10, 1994.

5. Reusch J, Hofeldt FD: Endocrine and nutritional disorders and heart disease. IN: Cardiology Secrets; Adaire OV and Havranek EP (eds); Hanley & Belfus, Inc. (publisher); 57:246-250, 1995.

6. Reusch JE-B: Diabetes and pregnancy. IN: Endocrinology Secrets; McDermott MT (ed); Hanley & Belfus, Inc. (publisher); 4:29-33, 1995.

7. Reusch JE-B, Sussman KE: Management of hyperglycemic emergencies and other hyperglycemic states. IN: Current Practice of Medicine; Korenman SG (ed); IV: 15.1-15.7, 1996.

8. Reusch JE-B (Discussant): Type II diabetes: Glucose homeostasis, complications, and novel therapies. IN: Report of the Fourteenth Ross Conference on Medical Research, Ross Products Division, Abbott Laboratories, Columbus, OH; 1995.

9. Reusch JE-B: New directions in treating insulin resistance. IN: Editorial Hospital Practice, 30:9-10, 1995.

10. Draznin B, Reusch JE-B: Insulin and intracellular ions. IN: Diabetes Mellitus: A fundamental and Clinical Text; LeRoith D, Taylor SI, Olefsky JM (eds); Lippincott-Raven Publishers, Philadelphia, PA, 1996; 227-234.

11. Regensteiner J, Reusch JE-B, Brandenberg S: The benefit of exercise for patients with NIDDM. IN: Clinical Research in Diabetes Mellitus; Draznin B, Rizza R (eds); Humana Press, Totowa, NJ, 1996.

12. Reusch JE-B: Management of hyperglycemic emergencies and other hyperglycemic states. IN: Current Practice of Medicine; Korenman SG (ed); 2nd Edition (in press 1998).

13. Reusch JE-B: Diabetes and pregnancy. IN: Endocrinology Secrets; McDermott MT (ed); 2nd

Edition, Hanley & Belfus, Inc. (publisher); pp. 29-33, 1998.

14. Reusch JE-B, Baxter J, Melmed S “Type 2 Diabetes Mellitus” New M eds. Genetics in Endocrinology, Lippincott-Raven (1998-inpress)

15. Draznin B, Reusch JE-B: Insulin and intracellular ions. IN: Diabetes Mellitus: A fundamental and Clinical Text; LeRoith D, Taylor SI, Olefsky JM (eds); 2nd Edition, Lippincott-Raven Publishers, Philadelphia, PA (In Press).

16. EC Ridgway and JEB Reusch Endocrinology, Metabolism and Diabetes chapter in The internal Medicine Handbook RW Schrier ED, Lippincott, Williams and Wilkins Second Ed 61-126, 2000.

17. Barbour L and Reusch JE-B: Diabetes and pregnancy. IN: Endocrinology Secrets; McDermott MT (ed); 3rd Edition, Hanley & Belfus, Inc. (publisher); pp. 29-33, 2000.

18. Brandenberg SL, Reusch JEB, Regensteiner JG Cardiovascular Disease in Women with Diabetes (Women’s Health in Primary Care 5. (4S) 28-34, 2002)

19. McCall D and Reusch JEB Pathophysiology of diabetic Vascular Disease (in preparation for The Endocrinologist invited by Robert R. Henry)

20. Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G, Lopes-Virella M, Reusch J, Ruderman N, Steiner G, Vlassara H “Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: Pathogenesis of Atherosclerosis in Diabetes” Circulation. 2002 May7;105(18):e138-43.

21. Reusch JEB, Brownlee M Mechanism of Diabetic Complications induced by Glucose, Yudkin

JS Editor International Textbook of Diabetes (2004)

22. Reusch JEB “Current Concepts in Insulin Resistance, Type 2 Diabetes Mellitus and the Metabolic Syndrome” Am J Cardiol. 2002 Sep 5;90(5A):19G-26G.

23. Reusch JE, Gadsby R “Thiazolidinedione therapy: the Benefits of Aggressive and early use in type 2 diabetes” Diabetes Technol Ther. 2003; 5(4):685-93.

24. Reusch JE, Watson PA, Regensteiner JG “Novel actions of thiazolidinediones on vascular function and exercise capacity” Am J Med. 2003 Dec 8;115 Suppl 8A:69S-74S.

25. Watson PA, Klemm DJ Reusch JEB “CREB and C/EBP proteins control Vascular Smooth Muscle Cell Fate” (Chapter) in Friedman JE editor Elsevier Press “New Transcription Factors and their role in Diabetes and its Therapies” 211-232, 2006)

  1. Reusch JEB and Watson PA “Loss of CREB Regulation of Vascular Smooth Muscle Cell Quiescence in Diabetes” Rev Endocr Metab Disord. 2004 Aug;5(3):209-19.

  2. Brandenburg SL, Lindenfeld J, Reusch JE, Regensteiner JG “Cardiovascular risk in women with type 2 diabetes” Med Clin North Am. 2003 Sep;87(5):955-69. Review.

  3. Nesto et al discussion group "Evaluating the Cardiovascular Effects of TZDs and their Place in the Management of T2D in Relation to the Metabolic Syndrome, Metabolic Syndrome and Related Disorders. 3: 147-173, 2005

29 . JEB Reusch and B Draznin “Atherosclerosis in Diabetes and Insulin Resistance” Diabetes Obes Metab. 9(4):455-6330 Jul 2007. PMID: 17587387

30. Huebschmann AG, Regensteiner RG, Vlassara H, Reusch JEB Diabetes and advanced glycoxidation end products. Diabetes Care. 2006 Jun; 29(6):1420-32. PMID: 16732039

31. Schauer IE and Reusch JEB (2007) Endocrinology, Metabolism, and Diabetes in: The Internal Medicine Handbook 3rd edition, ed. RW Schrier, Lippincott, Williams and Wilkins: Philadelphia, PA, pp. 70-140.

32. Schauer IE, Bauer T, Watson PA, Regensteiner JG, Reusch JEB (2008) Exercise Performance and Exercise Training in Diabetes. In: Diabetes and Exercise, eds. Regensteiner JG, Stewart K, Reusch JEB, Veves A; Humana Press. 2009.

33. Schauer, IE, Regensteiner, JG, and Reusch, JEB (2008) Effects of Exercise on Diabetes and Metabolic Syndrome in: “Metabolic Syndrome: Childhood Precursors and Adult disease” ed. Zeitler, P. 2009

34. Reusch JEB, Brar M Inpatient Management of Diabetes and Hyperglycemia Federal Practitioner 25 S4, 10-17, 2008

35. Reusch JEB, Brar M Insulin therapy in the Outpatient Setting, Federal Practitioner 25 S4, 18-23, 2008

36. Nadeau K, Reusch JEB, Regensteiner JA Exercise and Type 2 Diabetes in Youth Diabetes and Exercise, eds. Regensteiner JG, Stewart K, Reusch JEB, Veves A; Humana Press. 2009.

37. Jane EB Reusch and Cecilia Wang “Cardiovascular Disease and Diabetes; Where does glucose fit in? (JCEM invited Review-in press 2010)

38. Kristen J Nadeau and Jane EB Reusch ‘Cardiovascular Function/Dysfunction in Adolescents With Type 1 Diabetes” (Current Diabetes Reports Ed. Eugene Barrett- invited review-in press 2010)


In preparation or submitted:

  1. Peter A. Watson, Dwight Klemm, David F. Gordon, Danielle Haakinson , Charles Vinson, Albina Nesterova, Terry Wilkinson, and Jane E-B. Reusch. “Transcriptional Regulation of the Platelet-Derived Growth Factor Receptor Gene by Changes in Cyclic Nucleotide Regulatory Protein Function.” (In revision)

  2. Monique Lloyd, Leslie Knaub, Moarong Wang, Subbiah Pugazhenthi and Jane EB Reusch FFA regulation of CREB in Neurons is Biphasic (under revision)

  3. Pugazhenthi s, Lloyd M, Wang M, Reusch JEB Pioglitazone-induced activation of CREB through Akt in pancreatic beta cells (in preparation)



ABSTRACTS

  1. Rich S, Reusch J, Panter S, Barbosa J: Is there a genetic relationship between NIDDM & IDDM? 46th Annual Meeting ADA, Abstract #95, page 24A, 1986.

  2. Reusch JEB, Kolhouse F: ALL and hypereosinophilia. Colorado State ACP Conference 1988.

  3. Reusch JEB, Begum N, Draznin B: Mechanism of calcium induced insulin resistance. 73rd Annual Endocrine Society Meetings, Abstract #1375, 1991.

  4. Reusch JEB, Goralnik GN, Draznin B: Prognostic factors for success of intermittent fasting in the treatment of obese patients with NIDDM. Western Section, American Society for Clinical Investigation, Carmel, CA, Abstract #143A, 1992.

  5. Reusch JEB, Sussman KE, Draznin B: Phosphorylation of GLUT-4 impairs its intrinsic activity. American Diabetes Association, Abstract #710, 1992.

  6. Reusch JEB, Holcomb B, Hsieh P, Hoeffler J, Draznin B: Insulin inhibits nuclear phosphatase PP-2A to promote phosphorylation of the transcription factors ATF-1 and CREB. Carmel Abstract/Plenary Session, American Society for Clinical Investigation, Washington, D.C., Abstract #210A, 1993.

  7. Reusch JE-B, Hsieh PS, Carel K, Eisenbarth S, Draznin B: Posttranslational modification of transcription factors by insulin. Western Section, American Federation for Clinical Research, Abstract #26A, February 1994.

  8. Reusch JE-B, Hsieh PS, Carel K, Eisenbarth S, Draznin B: Posttranslational modification of transcription factors by insulin. American Diabetes Association, June 1994.

  9. Reusch JE-B, P Bhuripanyo, K Carel, P Hsieh, D DePaolo, JW Leitner, B Draznin: Differential pathways for mitogenic and metabolic signaling by insulin. American Federation for Clinical Research, Carmel, CA, February 1995.

  10. Reusch JE-B, Carel K, Leitner JW, Bhuripanyo P, Hsieh P, DePaolo D, Draznin B: Differential roles of Ras and PI-3 kinase in the mechanism of metabolic and mitogenic effects of insulin. American Diabetes Association, 1995.

  11. DePaolo D, Reusch JE-B, Carel K, Leitner JW, Draznin B: Inhibition of GAP activity by PI-3 kinase is involved in the mechanism of mitogenic signaling by insulin. Endocrine Society, 1995.

  12. Kummer JL, Reusch JE-B, Heidenreich KA: Insulin inhibits a novel mitogen-activated protein kinase (MAP) in cultured fetal neurons. Insulin-like Growth Factor Symposium, March 1995.

  13. Klemm DJ, Colton LA, Reusch JE-B, Roesler WJ: Insulin stimulates CREB phosphorylation and transcriptional activity. ASBMB, 1995.

  14. Lindenfeld J, Clarke S, Reusch JE-B, Manco-Johnson MJ, Lefkowitz JB, Regensteiner JG: Fibrinolysis is diminished in premenopausal non-insulin dependent diabetics. American Heart Association, 68th Session, 1995.

  15. Reusch JE-B, Felder K, Klemm D: Insulin regulation of CREB transcriptional activity requires the PKA site and a putative casein kinase II site. American Diabetes Association, #674, 1996.

  16. Reusch JE-B, Klemm D: Insulin activates CREB transcriptional activity: The requirement for PKA and putative casein kinase II phosphorylation sites. American Federation for Clinical Research, Carmel, CA, February 1996.

  17. Millard E, Felder K, Klemm DJ, Reusch JE-B: The MAP kinase pathway is essential for insulin regulation of CREB. American Federation for Medical Research, Carmel, CA, February 1997.

  18. Reusch JE-B, Boras T, Klemm DJ, Felder K: Insulin regulation of CREB is mediated by the Raf 16MEK6MAP-K pathway. Biomedicine '97, Washington, DC, April 1997.

  19. Reusch JE-B, Felder K, Klemm DJ, Boras T: Protein kinase C mimics insulin's activation of CREB but is not essential for insulin regulation. The Endocrine Society, 1997.

  20. Brandenburg SL, Hiatt WR, Bauer TA, Reusch JE-B, Vogelsong AM, Wolfel EE, Regensteiner JG: Slowed oxygen uptake kinetic responses in women with non-insulin dependent diabetes. J Invest Med 45:119A, 1997.

  21. Pugazhenthi S, Boras T, Heidenreich KA, Reusch JE-B: IGF-1 regulation of CREB transactivation in PC-12 cells: Contributions from redundant signaling pathways. American Diabetes Association 1998.

  22. Brandenburg SL, Felder KK, Lindenfeld J, Reusch JE-B, Regensteiner JG: Impaired fibrinolysis in premenopausal women with type 2 diabetes mellitus. American Federation for Medical Research 1998.

  23. Brandenburg SL, Bauer TA, Reusch JE-B, Hiatt WR, Regensteiner JG: Effect of exercise training on oxygen uptake kinetic responses in women with type 2 diabetes mellitus. Biomedicine 98 1998.

  24. Pugazhenthi S, Miller E, Sable C, Heidenreich K, Boxer L, Reusch JE-B: Induction of the BCL-2 promoter by p38b MAPK-mediated signaling pathway. Oral Presentation, Endocrine Society, 1999.

  25. Klemm DJ, Dempsey EC, Boras T, Watson PA, Reusch JE-B: Vascular smooth muscle cell phenotype correlates with CREB protein content. Oral Presentation American Diabetes Association, 1999.

  26. Gu J, Liu Y, Wen Y, Natarajan R, Lanting L, Reusch J, Nadler J: Overexpression of 12-lipoxygenase markedly increases apoptosis induced by serum withdrawal. Endocrine Society, 1999.

  27. Gill E, Weil J, Reusch JEB, Wolfel G, Hiatt W, Lindenfeld J, Quaife R, Regensteiner JA: Adiministration of L-arginine and antioxidants increases vasodilator function in women with type 2 DM Oral Presentation. American Heart Association 1999

  28. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, Reusch JEB: Akt/Protein Kinase B mediated cell survival involves transcriptional upregulation of bcl-2. WAFMR meetings Carmel CA Top Abstract in Neuroscience

  29. Pugazhenthi S, Nesterova A, Leasig T, Reusch JEB: Oxidative Stress diminishes Functional CREB content in Neurons. ADA San Antonio, 2000.

  30. Watson PA, Nestrova A, Klemm DJ, Reusch JEB: Diabetes Decreases Vascular CREB content and Altered SMC Function. Oral presentation ADA San Antonio, 2000.

  31. Pugazhenthi S, Rosner M, Eves EM, Masterson S, Reusch JEB: ROS disrupts CREB Function in Hippocampal Cell Lines. WAFMR meeting Carmel CA Feb 2001 and ADA meeting, Philadelphia PA, June 2001.

  32. Watson PA, Nesterova A, Dempsey EC, Reusch JEB: CREB is down-regulated in SMC by glucose mediated. ROS ADA meeting Philadelphia PA , June 2001.

  33. Reusch JEB: CREB downregulation in the vasculature by glucose mediated ROS: a nuclear switch for increased SMC proliferation in diabetes. EASD Glasgow, Scotland, September 2001.

  34. Watson PA, Pugazhenthi S, Nesterova A and Reusch JEB: Dysregulation of the PDGF Receptor in diabetes and insulin resistance is CREB Dependent. Endocrine Society, Denver, CO June 2001.

  35. Masterson S, Nesterova A, Boxer L, Hutton JC, Reusch JEB, Pugazhenthi S: Cytokines mediated downregulation of CREB function and bcl-2 expression in beta cells. Regional Islet conference, San Francisco, CA Sept 28-30, 2001

  36. Jambal P, Masterson S, Nesterova A, Boxer L, Hutton JC, Reusch JEB, Pugazhenthi S: Interleukin 1-beta Mediated Downregulation of CREB induced bcl-2 expression in Beta Cells. ADA oral abstract, San Francisco 2002
  1   2   3

Добавить документ в свой блог или на сайт

Похожие:

Jane Elizabeth-Brown Reusch, M. D icon1789. He was born in Boston, Massachusetts, to clock-maker Gawen Brown and Elizabeth Hill Adams Brown, Gawen Brown's third wife. Brown's publishing career

Jane Elizabeth-Brown Reusch, M. D iconJourney to East Asia by Jane P. Gardner and J. Elizabeth Mills

Jane Elizabeth-Brown Reusch, M. D iconColour: brown, mouthparts and legs (except hind tarsus and tibia in distal 7) slightly paler brown; wings infumate

Jane Elizabeth-Brown Reusch, M. D iconMy name is Dani Fernández Aguilera. I’m 13 years old. I have short brown hair and brown green eyes. I live in Santa Margarida de Montbui whith my parents and my

Jane Elizabeth-Brown Reusch, M. D iconVijay Amritraj is a lean an athletic man with dusky brown skin tones, close cropped wavy black hair, liquid brown eyes, a bristly moustache, and expressive

Jane Elizabeth-Brown Reusch, M. D icon1. robert1 steed. He married elizabeth in St Mary Brechin, Canterbury Kent. Child of robert steed and elizabeth is: I. George2 steed, b. April 26, 1790, Kent England. Generation No. 2 2

Jane Elizabeth-Brown Reusch, M. D icon1. eli1 holden he married elizabeth lnu. Child of eli holden and elizabeth lnu is: I. Eli2 holden, b. 02 Apr 1826, Shepley, Yorkshire, England; d. 26 Feb 1902. Generation No. 2 2

Jane Elizabeth-Brown Reusch, M. D iconJane E. Goodman

Jane Elizabeth-Brown Reusch, M. D iconSamuel Adams By Jane Runyon

Jane Elizabeth-Brown Reusch, M. D iconJane air — weekend warriors

Разместите кнопку на своём сайте:
kk.convdocs.org



База данных защищена авторским правом ©kk.convdocs.org 2012
обратиться к администрации
kk.convdocs.org
Главная страница